Studies in epigenetics have shown that DNA methylation is a key factor in regulating gene expression. Aberrant DNA methylation is often associated with DNA instability, which could lead to development of diseases such as cancer. DNA methylation typically occurs in CpG context. When located in a gene promoter, DNA methylation often acts to repress transcription and gene expression. The most commonly used technology of studying DNA methylation is bisulfite sequencing (BS-seq), which can be used to measure genomewide methylation levels on the single-nucleotide scale. Notably, BS-seq can also be combined with enrichment strategies, such as reduced representation bisulfite sequencing (RRBS), to target CpG-rich regions in order to save per-sample costs. A typical DNA methylation analysis involves identifying differentially methylated regions (DMRs) between different experimental conditions. Many statistical methods have been developed for finding DMRs in BS-seq data. In this workflow, we propose a novel approach of detecting DMRs using edgeR. By providing a complete analysis of RRBS profiles of epithelial populations in the mouse mammary gland, we will demonstrate that differential methylation analyses can be fit into the existing pipelines specifically designed for RNA-seq differential expression studies. In addition, the generalized linear model framework offers great edgeR flexibilities for complex experimental design, while still accounting for the biological variability. The analysis approach illustrated in this article can be applied to any BS-seq data that includes some replication, but it is especially appropriate for RRBS data with small numbers of biological replicates. 
Introduction
Studies in the past have shown that DNA methylation, as an important epigenetic factor, plays a vital role in genomic imprinting, X-chromosome inactivation and regulation of gene expression 1 . Aberrant DNA methylation is often correlated with DNA instability, which leads to development of diseases including imprinting disorders and cancer 2, 3 .
In mammals, DNA methylation almost exclusively occurs at CpG sites, i.e. regions of DNA where a cytosine (C) is linked by a phosphate (p) and bond to a guanine (G) in the nucleotide sequence from 5' to 3'. It has been found that 70% ∼ 80% of CpG cytosines are methylated in mammals, regardless of the cell type 4 . Unmethylated CpGs usually group together in clusters of regions known as CpG islands 5 , which cover about 2% of the entire genome. Around 40% of mammalian genes and 70% of human genes have CpG islands enriched in their promoter regions [6] [7] [8] . CpG methylation in gene promoters is generally associated with repression of transcription, and hence silencing of gene expression 5 . When occurring at the promoters of tumor suppressor gene, DNA methylation could repress the tumour suppressors, leading to oncogenesis 3 . In contrast, high levels of methylation have been observed in the gene body of highly expressed genes 9 , which implies positive correlation between gene body methylation and gene expression.
Among numerous existing technologies, the most widely used method to investigate DNA methylation is bisulfite sequencing (BS-seq), which produces data on the single-nucleotide scale 10 . Unmethylated cytosines (C) are converted to Uracils (U) by sodium bisulfite and then deaminated to thymines (T) during PCR amplification. Methylated Cs, on the other hand, remain intact after bisulfite treatment. The BS-seq technique can be used to measure genome-wide single-cytosine methylation levels by sequencing the entire genome. This strategy produces whole genome bisulfite sequencing (WGBS) data. However, the WGBS approach could be cost-prohibitive for species, such as human, with large genome. In addition, the fact that CpG islands reside in only 2% of the entire genome makes the WGBS approach inefficient when comparing a large number of samples.
To improve the efficiency and bring down the scale and cost of WGBS, enrichment strategies have been developed and combined with BS-seq to target a specific fraction of the genome. A common targeted approach is reduced representation bisulfite sequencing (RRBS) that targets CpG-rich regions 11 . Under the RRBS strategy, small fragments that compose only 1% of the genome are generated using MspI digestion, which means fewer reads are required to obtain accurate sequencing. The RRBS approach can capture approximately 70% of gene promoters and 85% of CpG islands, while requiring only small quantities of input sample 12 . In general, RRBS has great advantages in cost and efficiency when dealing with large scale data, whereas WGBS is more suitable for studies where all CpG islands or promoters across the entire genome are of interest.
The first step of analyzing BS-seq data is to align short reads to genome. The number of C-to-T conversions are then counted for all the mapped reads. A number of software tools have been developed for the purposes of read mapping and methylation calling of BS-seq data. Popular ones include Bismark 13 Typical downstream DNA methylation studies often involve finding differentially methylated regions (DMRs) between different experimental conditions. A number of statistical methods and software packages have been developed for detecting DMRs using the BS-seq technology. methylkit 19 and RnBeads 20 implement Fisher's Exact Test, which is a popular choice for two-group comparisons with no replicates. In the case of complex experimental designs, regression methods are widely used to model methylation levels or read counts. RnBeads offers a linear regression approach based on the moderated t-test and empirical Bayes method implemented in limma 21 . BSmooth 22 is another analysis pipeline that uses linear regression and empirical Bayes together with a local likelihood smoother. methylkit also has an option to apply logistic regression with overdispersion correction
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. Some other methods have been developed based on beta-binomial distribution to achieve better variance modelling. For example, DSS fits a Bayesian hierarchical beta-binomial model to BS-seq data and uses Wald tests to detect DMRs 23 . Other software using beta-binomial model include BiSeq 24 , MOABS 25 and RADMeth 26 .
In this workflow, we demonstrate an edgeR approach of differential methylation analysis. edgeR is one of the most popular Bioconductor packages for assessing differential expression in RNA-seq data 27 . It is based on the negative binomial (NB) distribution and it models the variation between biological replicates through the NB dispersion parameter. Unlike other approaches to methylation sequencing data, the analysis explained in this workflow keeps the counts for methylated and unmethylated reads as separate observations. edgeR linear models are used to fit the total read count (methylated plus unmethylated) at each genomic locus, in such a way that the proportion of methylated reads at each locus is modelled indirectly as an over-dispersed binomial distribution. This approach has a number of advantages. First, it allows the differential methylation analysis to be undertaken using existing edgeR pipelines developed originally for RNA-seq differential expression analyses. The edgeR generalized linear model (GLM) framework offers great flexibility for analysing complex experimental designs while still accounting for the biological variability. Second, keeping methylated and unmethylated read count as separate data observations allows the inherent variability of the data to be modeled more directly and perhaps more realistically. Differential methylation is assessed by likelihood ratio tests so we do not need to assume that the log-fold-changes or other coefficient estimators are normally distributed.
This article presents an analysis of an RRBS data set generated by the authors containing replicated RRBS profiles of basal and luminal cell populations from the mouse mammary epithelium. As with other articles in the Bioconductor Gateway series, our aim is to provide an example analysis with complete start to finish code. As with other Bioconductor workflow articles, we illustrate one analysis strategy in detail rather than comparing different pipelines. The analysis approach illustrated in this article can be applied to any BS-seq data that includes some replication, but is especially appropriate for RRBS data with small numbers of biological replicates. The results shown in this article were generated using Bioconductor Release 3.6.
The NB linear modeling approach to BS-seq data A small example To introduce the edgeR linear modeling approach to BS-seq data, consider a genomic locus that has m A methylated and u A unmethylated reads in condition A and m B methylated and u B unmethylated reads in condition B. Our approach is to model all four counts as NB distributed with the same dispersion but different means. Suppose the data is as given in Table 1 . If this were a complete dataset, then it could be analyzed in edgeR as follows.
> counts <-matrix(c(2,12,11,0),1,4) > dimnames(counts) <-list("Locus", c("A_Me","A_Un","B_Me","B_Un"))) > counts A_Me A_Un B_Me B_Un Locus 2 12 11 0 > design <-cbind(Sample1 = c(1,1,0,0), Sample2 = c(0,0,1,1), A_MvsU = c(1,0,1,0), BvsA_MvsU = c(0,0,1,0)) > fit <-glmFit(counts, design, lib.size=c(100,100,100,100), dispersion=0.0247) > lrt <-glmLRT(fit, coef="BvsA_MvsU") > topTags(lrt) Coefficient: BvsA_MvsU logFC logCPM LR PValue FDR Locus 8.99
16.3 20.7 5.27e-06 5.27e-06 In this analysis, the first two coefficients are used to model the total number of reads (methylated or unmethylated) for samples 1 and 2, respectively. Coefficient 3 (A_MvsU) estimates the log ratio of methylated to unmethylated reads for sample 1, a quantity that can also be viewed as the logit proportion of methylated reads in sample 1. Coefficient 4 (BvsA_MvsU) estimates the difference in logit proportions of mythylated reads between conditions B and A. The difference in logits is estimated here as 8.99 on the log2 scale. The P-value for differential methylation (B vs A) is P = 5.27 × 10 -6
.
The dispersion parameter controls the degree of biological variability
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. If we had set dispersion=0 in the above code, then the above analysis would be exactly equivalent to a logistic binomial regression, with the methylated counts as responses and the total counts as sizes, and with a likelihood ratio test for a difference in proportions between conditions A and B. Positive values for the dispersion produce over-dispersion relative to the binomial distribution. We have set the dispersion here equal to the value that is estimated below for the mammary epithelial data.
In the above code, the two library sizes for each sample should be equal. Otherwise, the library size values are arbitrary and any settings would have lead to the same P-value. The approach taken in this article is closely related to the beta-binomial approach but makes different and seemingly more natural assumptions about the NB distributions. We instead assume the two NB distributions to have the same dispersion but different means. The NB linear modeling approach allows the means and dispersions of the two NB distributions to be estimated separately, in concordance with the data instead of being artificially linked.
Relationship to beta-binomial modeling

Description of the biological experiment
Aim of the study The epithelium of the mammary gland exists in a highly dynamic state, undergoing dramatic morphogenetic changes during puberty, pregnancy, lactation, and regression 29 . Characterization of the lineage hierarchy of cells in the mammary epithelium is an important step toward understanding which cells are predisposed to oncogenesis. In this study, we profiled the methylation status of the two major functionally distinct epithelial compartments: basal and luminal cells. The basal cells were further divided into those showing high or low expression of the surface marker Itga5 as part of our investigation of heterogeneity within the basal compartment. We carried out global RRBS DNA methylation assays on two biological replicates of each of the three cell populations to determine whether the epigenetic machinery played a potential role in (i) differentiation of luminal cells from basal and (ii) any compartmentalization of the basal cells associated with Itga5.
Sample preparation
Inguinal mammary glands (minus lymph node) were harvested from FVB/N mice. All animal experiments were conducted using mice bred at and maintained in our animal facility, according to the Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee guidelines. Epithelial cells were suspended and fluorescence-activated cell sorting (FACS) was used to isolate basal and luminal cell populations 30 . Genomic DNA (gDNA) was extracted from freshly sorted cells using the Qiagen DNeasy kit. Around 25ng gDNA input was subjected to DNA methylation analysis by BS-seq using the Ovation RRBS Methyl-seq kit from NuGEN. The process includes MspI digestion of gDNA, sequencing adapter ligation, end repair, bisulfite conversion, and PCR amplification to produce the final sequencing library. The Qiagen EpiTect Bisulfite kit was used for bisulfite-mediated conversion of unmethylated cytosines. The experiment has a simple one-way layout with three groups. A single grouping factor is made as follows:
Experimental design
The sequencing was carried out on the Illumina NextSeq 500 platform. About 30 million 75bp paired-end reads were generated for each sample.
Differential methylation analysis at CpG loci
Processing bisulfite sequencing FASTQ files The first step of the analysis is to map the sequencing reads from the FASTQ files to the mouse genome and then perform methylation calls. Though many options are available, we use Bismark for read alignment and methylation calling. Bismark is one of the most popular software tools to perform alignments of bisulfite-treated sequencing reads to a genome of interest and perform methylation calls. It maps sequencing reads using the short read aligner Bowtie 1 18 or alternatively Bowtie 2 31 .
To increase alignment rates and reduce false methylation calls, it is recommended to trim poor quality reads on sequence ends and remove adapters that can be potentially sequenced prior to the alignment. This is done using trim_galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). After that, Bismark version v0.13.0 is used to align the reads to the mouse genome mm10. The final methylation calls are made using bismark_methylation_extractor.
Downloading the data
The Bismark outputs include one coverage bed file of the methylation in CpG context for each sample. The coverage outputs from Bismark are available at http://bioinf.wehi.edu.au/edgeR/F1000Research2017/. Readers wishing to reproduce the analysis presented in this article can download the zipped coverage bed files produced by Bismark from the above link.
Bed files can be read into R using read.delim as for txt files. Each of the bed files has the following format: 
Reading in the data
Since the start and end positions in the coverage outputs are identical for each CpG site, only one of them is needed for marking the location of each. We also ignore the methylation proportion as it can be directly calculated from the number of methylated and unmethylated Cs. The data can then be read into a list in R:
The data object is a list containing six data frames, each of which represents one sample. The first and second columns of each data frame are the chromosome numbers and positions of all the CpG loci observed in that sample. The last two columns contain the numbers of methylated and unmethylated Cs detected at those loci. Since the number of reported CpG loci varies across different samples, care is required to combine the information from all the samples. We first obtain all unique CpG loci observed in at least one of the six samples. This is done by combining the chromosome number and position of each CpG site. Then we extract read counts of methylated and unmethylated Cs at these locations across all the samples and combine them into a count matrix. The counts object is a matrix of integer counts with 12 columns, two for each sample. The odd number of columns contain the numbers of methylated Cs, whereas the even number of columns contain the numbers of unmethylated Cs. The genomic positions are used as the row names of the count matrix.
> rownames(counts) <-position_all > Sample2 <-rep(Sample, each=2) > Sample2 <-factor(Sample2) > Meth <-rep(c("Me","Un"), length(Sample)) > Meth <-factor(Meth, levels=c("Un","Me")) > colnames(counts) <-paste(Sample2, Meth, sep="-") > head(counts) We then proceed to the edgeR analysis of the methylation data. The edgeR package stores data in a simple list-based data object called a DGEList. We first create a DGEList object using the count matrix generated before. The information of CpG sites is converted into a data frame and stored in the genes component of the DGEList object.
> library(edgeR) > options(digits=3) > Chr <-gsub("-.*$", "", position_all) > Position <-gsub("^.*-", "", position_all) > Genes <-data.frame(Chr=Chr, Position=Position) > y <-DGEList(counts, genes=Genes, group=rep(Group,each=2))
Filtering to remove low counts We first sum up the read counts of both methylated and unmethylated Cs at each CpG site within each sample. CpG loci that have very low counts across all the samples shall be removed prior to downstream analysis as they provide little information for assessing methylation levels. As a rule of thumb, we require a CpG site to have a total count (both methylated and unmethylated) of at least 10 across all the samples before it is considered in the study.
> keep <-rowSums(counts_total >= 10) == 6 > The DGEList object is subsetted to retain only the non-filtered loci:
The option keep.lib.sizes=FALSE causes the library sizes to be recomputed after the filtering. This is generally recommended, although the effect on the downstream analysis is usually small.
Normalization
A key difference between BS-seq and other sequencing data is that the pair of libraries holding the methylated and unmethylated reads for a particular sample are treated as a unit. To ensure that the methylated and unmethylated reads for the same sample are treated on the same scale, we need to set the library sizes to be equal for each pair of libraries. We set the library sizes for each sample to be the average of the total read counts for the methylated and unmethylated libraries: Other normalization methods developed for RNA-seq data, such as TMM 32 , are not required for BS-seq data.
Exploring differences between samples
In DNA methylation studies, methylation levels are of most interest. For Illumina methylation assay, two common measurements of methylation levels are β-values and M-values, which are defined as β = M/(M+U) and M-value= log 2 (M/U) where M and U denote the methylated and unmethylated intensity 33 . Here we adopt the same idea and extend the two measurements to BS-seq data. That is, denote the methylated and unmethylated Cs by M and U respectively, and define the β-values and M-values in the same way as above.
In practice, for a particular CpG site in one sample, the M-value can be computed by subtracting the log2 count-per-million (CPM) of the unmethylated Cs from that of the methylated Cs. This is equivalent to the calculation of the defined M-values as the library sizes are set to be the same for each pair of methylated and unmethylated columns and they cancel each other out in the subtraction. A prior count of 2 is added to the calculation of log2-CPM to avoid undefined values and to reduce the variability of M-values for CpG sites with low counts. The calculation of β-value is straight-forward though a small offset may also be added to the calculation.
The outputs Beta and M are numeric matrices with six columns, each of which contains the β-values or M-values calculated at each CpG site in one sample. Then we can generate multi-dimensional scaling (MDS) plots to explore the overall differences between the methylation levels of the different samples. Here we decorate the MDS plots to indicate the cell groups:
> par(mfrow=c(1,2)) > plotMDS(Beta, col=rep(1:3, each=2), main="Beta-values") > plotMDS(M, col=rep(1:3, each=2), main="M-values") Figure 1 shows the resulting plots. In these plots, the distance between each pair of samples represents the average log-fold change between the samples for the top most differentially methylated CpG loci between that pair of samples. (We call this average the leading log-fold change.) The two replicate samples from the luminal population (P6) are seen to be well separated from the four basal samples (populations P7 and P8).
Design matrix
One aim of this study is to identify differentially methylated regions (DMRs) between different groups. In edgeR, this can be done by fitting linear models under a specified design matrix and testing for corresponding coefficients or contrasts. Here, a design matrix is constructed as follows:
> design <-model.matrix(~ Sample2 + Meth) > colnames(design) <-gsub("Sample2","",colnames(design)) > colnames(design) <-gsub("Meth","",colnames(design)) > colnames(design) [ in the P6 group. The 8th column "Me2" represents the difference in methylation level between the P7 and P6 groups. Finally, the last column "Me3" represents the difference in methylation level between the P8 and P6 groups.
Dispersion estimation
With the design matrix specified, we can now proceed to the standard edgeR pipeline and analyze the data in the same way as for RNA-seq data. Similar to the RNA-seq data, the variability between biological replicates has also been observed in bisulfite sequencing data. This variability can be captured by the NB dispersion parameter under the generalized linear model (GLM) framework in edgeR.
The mean-dispersion relationship of BS-seq data has been studied in the past and no apparent mean-dispersion trend was observed 23 . This is also verified through our own practice. Therefore, we would not consider a mean-dependent dispersion trend as we normally would for RNA-seq data. A common dispersion estimate for all the loci, as well as an empirical Bayes moderated dispersion for each individual locus, can be obtained from the estimateDisp function in edgeR:
> y <-estimateDisp(y, design=design, trend="none") > y$common.dispersion This returns a DGEList object with additional components (common.dispersion and tagwise. dispersion) added to hold the estimated dispersions. Here the estimation of trended dispersion has been turned off by setting trend="none". For this data, the estimated prior degrees of freedom (df) are infinite for all the loci, which implies all the CpG-wise dispersions are exactly the same as the common dispersion. A BCV plot is often useful to visualize the dispersion estimates, but it is not informative in this case.
Testing for differentially methylated CpG loci
We first fit NB GLMs for all the CpG loci using the glmFit function in edgeR.
> fit <-glmFit(y, design)
Then we can proceed to testing for differentially methylated CpG sites between different populations. One of the most interesting comparisons is between the basal (P7 and P8) and luminal (P6) groups. The contrast corresponding to any specified comparison can be constructed conveniently using the makeContrasts function:
> contr <-makeContrasts(BvsL=0.5*(Me2+Me3), levels=design)
The actual testing is performed using likelihood ratio tests (LRT) in edgeR.
> lrt <-glmLRT(fit, contrast=contr)
The top set of most differentially methylated (DM) CpG sites can be viewed with topTags:
> topTags(lrt) Here positive log-fold changes represent CpG sites that have higher methylation level in the basal population compared to the luminal population. The Benjamini-Hochberg multiple testing correction is applied to control the false discovery rate (FDR).
The total number of DM CpG sites identified at an FDR of 5% can be shown with decideTestsDGE. There are in fact more than 50,000 differentially methylated CpGs in this comparison: The differential methylation results can be visualized with an MD plot (see Figure 2 ): Here, pr is a GRanges class object that contains the genomic ranges of the promoters of all the known mouse genes in the annotation package.
Summarizing counts in promoter regions
We create another GRanges class object sites, which contains the genomic locations of all the observed CpG sites.
> Position <-as.numeric(Position) > sites <-GRanges(seqnames=Chr, ranges=IRanges(start=Position, end=Position)) Then we find the overlaps between the gene promoter regions and all the CpG sites in the data using findOverlaps.
> olap <-findOverlaps(query=pr, subject=sites) > olap
Hits object with 1522464 hits and 0 metadata columns: queryHits subjectHits <integer> <integer> [ The queryHits component of olap marks the indices of the promoter region as in pr, whereas the subjectHits component contains the indices of the CpG sites as in sites that overlap with the corresponding promoter regions.
The numbers of methylated and unmethylated CpGs overlapping with gene promoters are summed up for each promoter.
> counts2 <-counts[subjectHits(olap), ] > counts2 <-rowsum(counts2, queryHits(olap))
The integer matrix counts2 contains the total numbers of methylated and unmethylated CpGs observed within the promoter of each gene. Same as before, counts2 has 12 columns, two for each sample. The odd number of columns contain the numbers of methylated Cs, whereas the even number of columns contain the numbers of unmethylated Cs. The only difference is that each row of counts2 now represents a gene promoter instead of an individual CpG site.
The gene symbol information can be added to the annotation using the org.Mm.eg.db package. A DGEList object is created for the downstream edgeR analysis.
> ind <-as.numeric(rownames(counts2)) > rownames(counts2) <-pr$gene_id[ind]
> library(org.Mm.eg.db) > anno <-select(org.Mm.eg.db, keys=pr$gene_id, columns="SYMBOL", + keytype="ENTREZID") > anno <-data.frame(Symbol=anno$SYMBOL[ind]) > y2 <-DGEList(counts2, genes=anno, group=rep(Group,each=2))
We sum up the read counts of both methylated and unmethylated Cs at each CpG sites within each sample.
> counts2_total <-t(rowsum(t(counts2), Sample2))
Filtering to remove low counts Filtering is performed in the same way as before. Since each row represents a 3,000-bp-wide promoter region that contains multiple CpG sites, we would expect less filtering than before. > keep2 <-rowSums(counts2_total >= 10) == 6 > Exploring differences between samples Same as before, we measure the methylation levels of gene promoter regions using both β-values and M-values. A prior count of 2 is added to the calculation of log2-CPM to avoid undefined values and to reduce the variability of M-values for gene promoters with low counts. Then MDS plots are produced to examine the overall differences between the methylation levels of the different samples. The resulting Figure 3 shows that the two replicate samples from the luminal population (P6) are well separated from the four replicate samples from the basal population (P7 and P8).
Dispersion estimation
We estimate the NB dispersions using the estimateDisp function in edgeR. For the same reason, we do not consider a mean-dependent dispersion trend as we normally would for RNA-seq data.
> y2 <-estimateDisp(y2, design=design, trend="none", robust=TRUE) > y2$common.dispersion The dispersion estimates can be visualized with a BCV plot (see Figure 4 ):
Testing for differential methylation in gene promoters We first fit NB GLMs for all the gene promoters using glmFit.
> fit2 <-glmFit(y2, design)
Then we can proceed to testing for differentially methylation in gene promoter regions between different populations. Suppose the comparison of interest is same as before. The same contrast can be used for the testing.
> lrt2 <-glmLRT(fit2, contrast=contr) Here positive log-fold changes represent gene promoters that have higher methylation level in the basal population compared to the luminal population. The Benjamini-Hochberg multiple testing correction is applied to control the false discovery rate (FDR). The differential methylation results can be visualized with an MD plot (see Figure 5 ):
Correlate with RNA-seq profiles RNA-seq profiles of mouse epithelium To show that DNA methylation (particularly in the promoter regions) represses gene expression, we relate the differential methylation results to the gene expression profiles of the RNA-Seq data. The RNA-seq data used here is from a study of the epithelial cell lineage in the mouse mammary gland 34 , in which the expression profiles of basal stem-cell enriched cells and committed luminal cells in the mammary glands of virgin, pregnant and lactating mice were examined. The complete differential expression analysis of the data is described in Chen et al. The RNA-seq data is stored in the format of a DGEList object y_rna and saved in a RData file rna.RData. The object y_rna contains the count matrix, sample information, gene annotation, design matrix and dispersion estimates of the RNA-seq data. The gene filtering, normalization and dispersion estimation were performed in the same way as described in Chen et al. 35 . The DE analysis between the basal and luminal in the virgin mice was performed using glmTreat with a fold-change threshold of 3. The results are saved in the spread sheet BvsL-fc3.csv. Both rna.RData and BvsL-fc3.csv are available for download at http://bioinf.wehi.edu.au/ edgeR/F1000Research2017/.
We load the RData file and read in the DE results from the spread sheet.
> load("rna.RData") > y_rna Correlation between the two datasets We select the genes of which the promoters are significantly DM (FDR < 0.05) and examine their expression level in the RNA-Seq data. A data frame object lfc is created to store the gene information, log-fold change of methylation level and log-fold change of gene expression of the selected genes.
> tp <-topTags(lrt2, n=Inf, p=0.05)$ The Pearson correlation coefficient between the two log-fold changes of the selected genes is estimated. The result shows high negative correlation between gene expression and methylation in gene promoters.
> cor(lfc$ME, lfc$RNA)
The log-fold changes of the selected genes from the two datasets are plotted against each other for visualization (see Figure 6 ):
> plot(lfc$ME, lfc$RNA, main="Basal vs Luminal", xlab="log-FC Methylation", + ylab="log-FC Gene Expression", pch=16, cex=0.8, col="gray30") > abline(h=0, v=0, col="gray10", lty=2, lwd=2) The horizontal axis of the scatterplot shows the log-fold change in methylation level for each gene while the vertical axis shows the log-fold change in expression. To assess the correlation, we fit a least squares regression line through the origin and compute the p-value: > u <-lm(lfc$RNA ~ 0 + lfc$ME)
> coef(summary(u))
Estimate Std. Error t value Pr(>|t|) lfc$ME -0.739 0.0473 -15.6 1.08e-47 > abline(u, col="red", lwd=2)
The negative association is highly significant (P = 10 -47 ). The last line of code adds the regression line to the plot (Figure 6 ).
Gene set testing
A rotation gene set test can be performed to further examine the relationship between gene expression and methylation in gene promoters. This is to test whether the set of genes (i.e., genes of which the promoters are differentially methylated) are differentially expressed (DE) and in which direction they are DE.
The indices are made by matching the Entrez Gene Ids between the two datasets. The log-fold changes of methylation level in gene promoters are used as weights for those genes. The test is conducted using the fry function in edgeR. The contrast is set to compare basal with luminal in virgin mice.
> ME <-data.frame(GeneID=row.names(lfc), weights=lfc$ME) > fry(y_rna, index=ME, design=y_rna$design, contrast=c(0,0,1,0,0,-1)) NGenes Direction PValue PValue.Mixed set1 731 Down 1.51e-09 7.17e-11
The small PValue indicates the significant testing result. The result Down in the Direction column indicates negative correlation between the methylation and gene expression.
We can visualize the gene set results with a barcode plot (see 
Packages used
This workflow depends on various packages from version 3.6 of the Bioconductor project, running on R version 3.4.0 or higher. Most of the workflow also works with Bioconductor 3.5, but the code in the last section (Correlate with RNA-seq samples) requires some minor changes for use with Bioconductor 3.5 because the earlier version of topTags did not preserve row names in the output appropriately combine samples with different sets of CpGs, and return a SummarizedExperiment -derived object (a instance) which could readily be used to construct the used in BSseq DGEList the analysis. In my experience, loading the data and combining different sets of loci is a step fraught with danger of hard-to-track-down errors, so it may be better to advise workflow users to use a fairly well-tested function. Full disclosure: I am the author of `bsseq::read.bismark()`. p14: The aggregation of CpGs to promoters may lead to surprising results. An (extreme) example: the first half of a promoter is methylated in one condition and unmethylated in the other, and vice versa for the second half of the promoter. In aggregate over the promoter the proportion of methylated CpGs may be similar in both conditions, yet this promoter is clearly differentially methylated. I think a note encouraging workflow users to think carefully about their hypothesis when doing this form of aggregation is warranted.
Grant information
Minor points
p1: "The most commonly used technology of studying DNA methylation is bisulfite sequencing (BS-seq)". The Illumina 27k/450k/EPIC microarrays are the most commonly used 'genome-wide' assays for studying DNA methylation. However, (whole genome) BS-seq is arguably the gold standard genome-wide assay. # CGIs in hg19 library(rtracklayer) my_session <-browserSession("UCSC") genome(my_session) <-"hg19" cgi <-track(ucscTableQuery(my_session, track = "cpgIslandExt")) sum(width(cgi)) / hg19_sizè``p 3: Possible type, "with large genome" a p3: "WGBS is more suitable for studies where all CpG islands or promoters across the entire genome are of interest." Might also add 'distal regulatory elements' and CG-poor regions (RRBS targets CG-rich regions of the genome). p3:
(implemented in ) doesn't use Empirical Bayes although it does use for BSmooth bsseq limma linear regression p4: Missing a `library(edgeR)` in order for the code to work p4: There's an extra parenthesis at the end of line 2 when constructing `dimnames(counts)p 4: The authors note that the method is "especially appropriate for RRBS data". Is the main challenge for running on WGBS data that of computational resources? p5: Typo, "mythlyated" should be "methylated" p5: Typo, "mythlyated" should be "methylated" Table 1 : Condition should be 'A' or 'B' instead of '1' or '2' p6: Was Bowtie1 or Bowtie2 used as the Bismark backend for the mouse data? p8: The filtering step removes almost 90% of CpGs. Is this unavoidable, e.g., due to low sequencing coverage of these samples, or might the filtering be relaxed? analyze RRBS data, but to a certain extent is also a methods paper, as to my knowledge this is the first proposal for directly analyzing count data rather than converting to either ratios and using a beta-binomial, or to logits and using conventional linear modeling. This is an interesting idea, and should be explored further, but for this manuscript the main goal is to present the software pipeline.
Simon Andrews
Bioinformatics Group, Babraham Institute, Cambridge, UK Chen present an interesting re-application of the EdgeR analysis package to the analysis of et al bisulphite sequencing data. The method they propose would utilise the existing negative biomial models within EdgeR and would potentially provide the power which comes with the linear model framework to bisulphite data. The method described requires no changes to EdgeR itself, and merely describes a suitable formulation of design matrix to allow this to be applied to bisulphite data.
The article is generally well written and the authors go to great lengths to break down and describe the method. They also provide a page from which all of the underlying data and code can be obtained and I was able to reproduce the results, and independently verify them in a parallel analysis.
The main thing which I struggled with was some of the detail in the description of the method itself. There were some parts which I wasn't clear on, and some nomenclature which didn't help in understanding the explanation. I'll try to lay out my concerns below: 1) In the small example I completely understand that the authors wanted to keep this as simple as possible, but it might have helped to have had 2 samples per condition so that the full complexity of the method is visible.
2) There is a typo in the code for the small example so it doesn't run as is. The list function on line 2 has an extra bracket at the end.
3) The nomenclature in the small example is inconsistent. You have samples 1 and 2, but (in the table) also conditions 1 and 2, but in the code the conditions are A and B. If you had Samples 1,2,3,4 in conditions A and B this might help to alleviate some of the confusion. 4) In the small example description you say that A_MvsU estimates the log ratio for Sample1, but it wasn't clear to me why this would apply to only Sample 1 since the factor has a 1 against the meth count for both samples 1 and 2
In the expanded examples there were also some points on which I wasn't clear. 5) You calculate a single dispersion parameter for all data points and say that in contrast to RNA-Seq there is no global trend to follow. It wasn't clear to be exactly why this is since read count and methlyation level would all affect the dispersion -is it simply because these factors are explicitly accounted for in the linear model? 6) In the design matrix for the RRBS it wasn't clear why the first column was all 1s, whereas the rest obviously matched the condition from which they came. This also contrasted with the simple example where the structure wasn't like this. Is this because you were comparing both P7 and P8 to P6? 7) I think this is possibly the same thing as point 4, but you say that the Me column represents the methylation level in P6, but again this highlights the methylated values in all samples, so why only P6?
For the final results obtained it would have been nice to show the general level of concordance with running the same analysis through one of the beta-distribution models to either show general agreement, or to generally explain any major differences.
